Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules (苁蓉舒痉颗粒) in Patients with Parkinson’s Disease and Syndrome of Shen (Kidney) Essence Deficiency
Authors:
- 14 April 2020
- journal article
- research article
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 26 (6) , 412-419
Abstract
Abstract Objective: To evaluate the clinical efficacy and safety of Congrong Shujing Granules (苁蓉舒 痉颗粒, CSGs) in treating patients with Parkinson’s disease (PD) and Chinese medicine (CM) syndrome of Shen (Kidney) essence deficiency, and to investigate the potential mechanism involving efficacy through a transcriptome sequencing approach. Methods: Eligible PD patients with syndrome of Shen essence defificiency were randomly assigned to a treatment group or a control group by a random number table, and were treated with CSGs combined with Western medicine (WM), or placebo combined with WM, respectively. Both courses of treatment lasted for 12 weeks. The Unifified Parkinson’s Disease Rating Scale (UPDRS) score, the PD Question-39 (PDQ-39) score, CM Syndrome Scale score, and drug usage of all patients were evaluated before and after treatment. Safety was evaluated by clinical laboratory tests and electrocardiographs. Blood samples from 6 patients in each group were collected before and after the trial and used for transcriptomic analysis by gene ontology analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Differentially expressed genes were validated using reverse transcription-polymerase chain reaction. Results: A total of 86 PD patients were selected from the Third Affifiliated People’s Hospital of Fujian University of Traditional Chinese Medicine between January 2017 and December 2017. Finally, 72 patients completed the trial, including 35 in the treatment group and 37 in the control group. When compared with the control group after treatment, patients in the treatment group showed signifificant decreases in UPDRS sub-II score, PDQ-39 score, CM syndrome score, and Levodopa equivalent dose (PP>0.05). A possible mechanism of clinical effificacy was proposed that involved regulating cell metabolism-related processes and ribosome-related pathways. Treatment with CSGs had shown to affect relevant gene loci for PD, including AIDA, ANKRD36BP2, BCL2A1, BCL2L11, FTH1P2, GCH1, HPRT1, NFE2L2, RMRP, RPS7, TGFBR1, WIPF2, and COX7B. Conclusions: CSGs combined with WM can be used to treat PD patients with CM syndrome of Shen essence defificiency with a good safety. The possible mechanism of action and relevant gene loci were proposed. (Registration No. ChiCTR-IOR-16008394)Keywords
This publication has 21 references indexed in Scilit:
- HISAT: a fast spliced aligner with low memory requirementsNature Methods, 2015
- StringTie enables improved reconstruction of a transcriptome from RNA-seq readsNature Biotechnology, 2015
- Clinical spectrum of levodopa‐induced complicationsMovement Disorders, 2014
- Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapyChinese Journal of Integrative Medicine, 2014
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Transdermal rotigotine for the perioperative management of Parkinson’s diseaseJournal of Neural Transmission, 2010
- A scaling normalization method for differential expression analysis of RNA-seq dataGenome Biology, 2010
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007
- Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndromeMovement Disorders, 2004
- ParkinsonismNeurology, 1967